A Phase 2 Trial of ALIMTA (LY231514, Pemetrexed) Plus Oxaliplatin Administered Every 21 Days for First-Line Treatment of Patients With Advanced Colorectal Cancer.

This study has been completed.

Study NCT00034619 Information provided by Eli Lilly and Company

First Received: May 1, 2002 Last Updated: July 18, 2006 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study has been completed.
Estimated Study Completion Date:	No date given
Estimated Primary Completion Date:	No date given